NUC 1031

Drug Profile

NUC 1031

Alternative Names: Acelarin; CPF-31; Gemzar ProTide - NuCana; MTL-007; NUC-1031

Latest Information Update: 13 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cardiff University
  • Developer Imperial College of Science, Technology and Medicine; NuCana
  • Class Antineoplastics
  • Mechanism of Action DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Pancreatic cancer
  • Phase II Ovarian cancer
  • Phase I/II Solid tumours
  • Phase I Biliary cancer; Bladder cancer; Non-small cell lung cancer

Most Recent Events

  • 12 Sep 2017 Imperial College Healthcare NHS Trust completes a phase I trial in Ovarian cancer (Combination therapy, Recurrent) in United Kingdom (IV) (NCT02303912)
  • 12 Sep 2017 Updated efficacy and adverse events data from the phase Ib ProGem2 trial in Ovarian cancer released by NuCana
  • 08 Sep 2017 Efficacy, pharmacokinetics and adverse events data from the phase Ib ProGem2 study in Ovarian cancer presented at the 42nd European Society for Medical Oncology Congress (ESMO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top